The DOI matches its Crossref record; 125 of the 125 references it cites were found in a registry or an index.
Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling
Open accessAbstract
The successful treatment of certain autoimmune conditions with the humanized anti-IL-6 receptor (IL-6R) antibody tocilizumab has emphasized the clinical importance of cytokines that signal through the β-receptor subunit glycoprotein 130 (gp130).In this Review, we explore how gp130 signaling controls disease progression and examine why IL-6 has a special role among these cytokines as an inflammatory regulator.Attention will be given to the role of the soluble IL-6R, and we will provide a perspective into the clinical blockade of IL-6 activity in autoimmunity, inflammation, and cancer.Conflict of interest: Stefan Rose-John is an inventor on the patent describing the function of sgp130Fc.He is also a shareholder of the CONARIS Research Institute (Kiel, Germany), which is commercially developing sgp130Fc as a therapy for inflammatory diseases.Simon A. Jones has a consultancy agreement with Roche Pharmaceuticals and advises research relating to the clinical introduction of Actemra/RoActemra.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
STATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383 · cited 1×
“STAT3 activity often correlates with tumorigenesis and is associated with tumor growth, survival, angiogenesis, and metastatic processes, including epithelial-mesenchymal transition, degradation of extracellular matrix, and cell migration (100, 101).”
BackgroundVeldhoen, M., Hocking, R. J., Atkins, C. J., Locksley, R. M., & Stockinger, B. (2006) · Immunity · doi:10.1016/j.immuni.2006.01.001 · Cited by 3,605
Principles of interleukin (IL)-6-type cytokine signalling and its regulation
HEINRICH, P. C., BEHRMANN, I., HAAN, S., HERMANNS, H. M., MÜLLER-NEWEN, G., & SCHAPER, F. (2003) · Biochemical Journal · doi:10.1042/bj20030407 · Cited by 3,272 · cited 7×
“IL-6 is traditionally considered a regulator of acute phase inflammatory responses and a lymphocyte stimulatory factor (14).”
BackgroundInfluentialCytokines in the pathogenesis of rheumatoid arthritis
McInnes, I. B., & Schett, G. (2007) · Nature Reviews Immunology · doi:10.1038/nri2094 · Cited by 2,529
Grivennikov, S., Karin, E., Terzic, J., Mucida, D., Yu, G.-Y., Vallabhapurapu, S., Scheller, J., Rose-John, S., Cheroutre, H., Eckmann, L., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.001 · Cited by 2,155
Self-citationGender Disparity in Liver Cancer Due to Sex Differences in MyD88-Dependent IL-6 Production
Naugler, W. E., Sakurai, T., Kim, S., Maeda, S., Kim, K., Elsharkawy, A. M., & Karin, M. (2007) · Science · doi:10.1126/science.1140485 · Cited by 1,955
Impaired immune and acute-phase responses in interleukin-6-deficient mice
Kopf, M., Baumann, H., Freer, G., Freudenberg, M., Lamers, M., Kishimoto, T., Zinkernagel, R., Bluethmann, H., & Köhler, G. (1994) · Nature · doi:10.1038/368339a0 · Cited by 1,768 · cited 2×
“In particular, IL-6–deficient (IL-6KO) mice are viable but show numerous immunological defects (15).”
BackgroundAtreya, R., Mudter, J., Finotto, S., Müllberg, J., Jostock, T., Wirtz, S., Schütz, M., Bartsch, B., Holtmann, M., Becker, C., et al. (2000) · Nature Medicine · doi:10.1038/75068 · Cited by 1,293
Self-citationGenome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci
BIRAC Consortium, Stahl, E. A., YEAR Consortium, Raychaudhuri, S., Remmers, E. F., Xie, G., Eyre, S., Thomson, B. P., Li, Y., Kurreeman, F. A. S., et al. (2010) · Nature Genetics · doi:10.1038/ng.582 · Cited by 1,253
Waage, A., Brandtzaeg, P., Halstensen, A., Kierulf, P., & Espevik, T. (1989) · The Journal of experimental medicine · doi:10.1084/jem.169.1.333 · Cited by 1,173
Cited by
Effective treatment of severe COVID-19 patients with tocilizumab
Xu, X., Han, M., Li, T., Sun, W., Wang, D., Fu, B., Zhou, Y., Zheng, X., Yang, Y., Li, X., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2005615117 · Cited by 2,647
IL-6 as a keystone cytokine in health and disease
Hunter, C. A., & Jones, S. A. (2015) · Nature Immunology · doi:10.1038/ni.3153 · Cited by 2,511
Self-citationRevisiting STAT3 signalling in cancer: new and unexpected biological functions
Yu, H., Lee, H., Herrmann, A., Buettner, R., & Jove, R. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3818 · Cited by 2,137
Cytokine storm and sepsis disease pathogenesis
Chousterman, B. G., Swirski, F. K., & Weber, G. F. (2017) · Seminars in Immunopathology · doi:10.1007/s00281-017-0639-8 · Cited by 1,330
Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer
Jones, S. A., & Jenkins, B. J. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0066-7 · Cited by 1,102
Self-citationRole of interleukin-6 in cancer progression and therapeutic resistance
Kumari, N., Dwarakanath, B. S., Das, A., & Bhatt, A. N. (2016) · Tumor Biology · doi:10.1007/s13277-016-5098-7 · Cited by 1,092
Interleukin-6, a Major Cytokine in the Central Nervous System
Erta, M., Quintana, A., & Hidalgo, J. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.4679 · Cited by 1,087
Rose-John, S. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.4989 · Cited by 1,040
“Since all cells in the body express gp130 [9, 10], theoretically, all cells can be activated by the IL-6/sIL-6R complex.”
BackgroundSelf-citationGhosh, T. S., Rampelli, S., Jeffery, I. B., Santoro, A., Neto, M., Capri, M., Giampieri, E., Jennings, A., Candela, M., Turroni, S., et al. (2020) · Gut · doi:10.1136/gutjnl-2019-319654 · Cited by 991
Interleukin-6 Family Cytokines
Rose-John, S. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028415 · Cited by 799
Self-citationImmunotherapeutic Implications of Il-6 Blockade for Cytokine Storm
Tanaka, T., Narazaki, M., & Kishimoto, T. (2016) · Immunotherapy · doi:10.2217/imt-2016-0020 · Cited by 708
Ectopic lymphoid-like structures in infection, cancer and autoimmunity
Pitzalis, C., Jones, G. W., Bombardieri, M., & Jones, S. A. (2014) · Nature Reviews Immunology · doi:10.1038/nri3700 · Cited by 698
Self-citationCurrent and emerging therapeutic targets for IBD
Neurath, M. F. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.208 · Cited by 691
Interleukin-6: designing specific therapeutics for a complex cytokine
Garbers, C., Heink, S., Korn, T., & Rose-John, S. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.45 · Cited by 643
Self-citationInterleukin-6 and its receptors: a highly regulated and dynamic system
Wolf, J., Rose-John, S., & Garbers, C. (2014) · Cytokine · doi:10.1016/j.cyto.2014.05.024 · Cited by 618
“As a possible drug for treatment of inflammatory diseases, an optimized version of this inhibitor (FE999301) is currently tested in clinical phase I studies by Ferring Pharmaceuticals [4,20].”
BackgroundSelf-citationNOD2-mediated dysbiosis predisposes mice to transmissible colitis and colorectal cancer
Couturier-Maillard, A., Secher, T., Rehman, A., Normand, S., De Arcangelis, A., Haesler, R., Huot, L., Grandjean, T., Bressenot, A., Delanoye-Crespin, A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci62236 · Cited by 572
Metalloproteinases and their natural inhibitors in inflammation and immunity
Khokha, R., Murthy, A., & Weiss, A. (2013) · Nature reviews. Immunology · doi:10.1038/nri3499 · Cited by 552
Targeting IL-6 trans-signalling: past, present and future prospects
Rose-John, S., Jenkins, B. J., Garbers, C., Moll, J. M., & Scheller, J. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-023-00856-y · Cited by 524
Self-citationInterleukin-6: Biology, signaling and strategies of blockade
Schaper, F., & Rose-John, S. (2015) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2015.07.004 · Cited by 509
Self-citationTherapeutically exploiting STAT3 activity in cancer — using tissue repair as a road map
Huynh, J., Chand, A., Gough, D., & Ernst, M. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-018-0090-8 · Cited by 504
The role of interleukin-6 signaling in nervous tissue
Rothaug, M., Becker-Pauly, C., & Rose-John, S. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.03.018 · Cited by 491
“However, IL-6 signaling is also a major trigger for the onset and progression of many pathological conditions, such as rheumatoid arthritis [19,20], inflammatory bowel disease [21] or sepsis [22], and is therefore a chief focus of pharmaceutical research [23].”
BackgroundThe Immunobiology of the Interleukin-12 Family: Room for Discovery
Tait Wojno, E. D., Hunter, C. A., & Stumhofer, J. S. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.011 · Cited by 482
Bonetto, A., Aydogdu, T., Jin, X., Zhang, Z., Zhan, R., Puzis, L., Koniaris, L. G., & Zimmers, T. A. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00039.2012 · Cited by 463
The IL-6/gp130/STAT3 signaling axis: recent advances towards specific inhibition
Garbers, C., Aparicio-Siegmund, S., & Rose-John, S. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.02.008 · Cited by 429
Self-citationThe role of IL-6 in host defence against infections: immunobiology and clinical implications
Rose-John, S., Winthrop, K., & Calabrese, L. (2017) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2017.83 · Cited by 424
Self-citationInterleukin-6 - A Key Regulator of Colorectal Cancer Development
Waldner, M. J., Foersch, S., & Neurath, M. F. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.4614 · Cited by 418
Peirce, V., Carobbio, S., & Vidal-Puig, A. (2014) · Nature · doi:10.1038/nature13477 · Cited by 415
How Cytokine Networks Fuel Inflammation: Toward a cytokine-based disease taxonomy
Schett, G., Elewaut, D., McInnes, I. B., Dayer, J.-M., & Neurath, M. F. (2013) · Nature Medicine · doi:10.1038/nm.3260 · Cited by 406
Plasticity and cross-talk of Interleukin 6-type cytokines
Garbers, C., Hermanns, H. M., Schaper, F., Müller-Newen, G., Grötzinger, J., Rose-John, S., & Scheller, J. (2012) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2012.04.001 · Cited by 400
Self-citationEmerging cytokine networks in colorectal cancer
West, N. R., McCuaig, S., Franchini, F., & Powrie, F. (2015) · Nature Reviews Immunology · doi:10.1038/nri3896 · Cited by 396
The Biology and Medical Implications of Interleukin-6
Tanaka, T., & Kishimoto, T. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0022 · Cited by 375
Interleukin-6 Signaling Drives Fibrosis in Unresolved Inflammation
Fielding, C. A., Jones, G. W., McLoughlin, R. M., McLeod, L., Hammond, V. J., Uceda, J., Williams, A. S., Lambie, M., Foster, T. L., Liao, C.-T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2013.10.022 · Cited by 371
Self-citationZhang, W., Nandakumar, N., Shi, Y., Manzano, M., Smith, A., Graham, G., Gupta, S., Vietsch, E. E., Laughlin, S. Z., Wadhwa, M., et al. (2014) · Science Signaling · doi:10.1126/scisignal.2005049 · Cited by 360
Gukovsky, I., Li, N., Todoric, J., Gukovskaya, A., & Karin, M. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.02.007 · Cited by 343
Kern, L., Mittenbühler, M., Vesting, A., Ostermann, A., Wunderlich, C., & Wunderlich, F. (2018) · Cancers · doi:10.3390/cancers11010024 · Cited by 331
Interleukin-6: from an inflammatory marker to a target for inflammatory diseases
Rincon, M. (2012) · Trends in Immunology · doi:10.1016/j.it.2012.07.003 · Cited by 328
IL-6 biology: implications for clinical targeting in rheumatic disease
Calabrese, L. H., & Rose-John, S. (2014) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2014.127 · Cited by 328
Self-citationFerreira, R. C., Freitag, D. F., Cutler, A. J., Howson, J. M. M., Rainbow, D. B., Smyth, D. J., Kaptoge, S., Clarke, P., Boreham, C., Coulson, R. M., et al. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003444 · Cited by 316
Cevenini, E., Monti, D., & Franceschi, C. (2013) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/mco.0b013e32835ada13 · Cited by 317
“treatment in the elderly may be improved by the inhibition of proinflammatory cytokines by exploiting currently available antibodies used in chronic inflammatory diseases [25,26].”
BackgroundChen, L., Wilson, J. E., Koenigsknecht, M. J., Chou, W.-C., Montgomery, S. A., Truax, A. D., Brickey, W. J., Packey, C. D., Maharshak, N., Matsushima, G. K., et al. (2017) · Nature Immunology · doi:10.1038/ni.3690 · Cited by 310
New targets for mucosal healing and therapy in inflammatory bowel diseases
Neurath, M. F. (2014) · Mucosal Immunology · doi:10.1038/mi.2013.73 · Cited by 309
Interleukin-6: from basic biology to selective blockade of pro-inflammatory activities
Scheller, J., Garbers, C., & Rose-John, S. (2014) · Seminars in Immunology · doi:10.1016/j.smim.2013.11.002 · Cited by 308
Self-citationMasjedi, A., Hashemi, V., Hojjat-Farsangi, M., Ghalamfarsa, G., Azizi, G., Yousefi, M., & Jadidi-Niaragh, F. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.09.177 · Cited by 303
Selected cytokine pathways in rheumatoid arthritis
Noack, M., & Miossec, P. (2017) · Seminars in Immunopathology · doi:10.1007/s00281-017-0619-z · Cited by 303
Blockade of IL-6 Trans Signaling Attenuates Pulmonary Fibrosis
Le, T.-T. T., Karmouty-Quintana, H., Melicoff, E., Le, T.-T. T., Weng, T., Chen, N.-Y., Pedroza, M., Zhou, Y., Davies, J., Philip, K., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302470 · Cited by 299
New fronts emerge in the influenza cytokine storm
Guo, X.-Z. J., & Thomas, P. G. (2017) · Seminars in Immunopathology · doi:10.1007/s00281-017-0636-y · Cited by 297
IL-6 trans-signaling promotes pancreatitis-associated lung injury and lethality
Zhang, H., Neuhöfer, P., Song, L., Rabe, B., Lesina, M., Kurkowski, M. U., Treiber, M., Wartmann, T., Regnér, S., Thorlacius, H., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64931 · Cited by 288
Self-citationInterleukin-6: obstacles to targeting a complex cytokine in critical illness
McElvaney, O. J., Curley, G. F., Rose-John, S., & McElvaney, N. G. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00103-x · Cited by 278
Self-citationVascular niche IL-6 induces alternative macrophage activation in glioblastoma through HIF-2α
Wang, Q., He, Z., Huang, M., Liu, T., Wang, Y., Xu, H., Duan, H., Ma, P., Zhang, L., Zamvil, S. S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03050-0 · Cited by 277
Wörmann, S. M., Song, L., Ai, J., Diakopoulos, K. N., Kurkowski, M. U., Görgülü, K., Ruess, D., Campbell, A., Doglioni, C., Jodrell, D., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.03.010 · Cited by 276
Self-citationSindhu, S., Thomas, R., Shihab, P., Sriraman, D., Behbehani, K., & Ahmad, R. (2015) · PLOS ONE · doi:10.1371/journal.pone.0133494 · Cited by 265
Jordan, S. C., Choi, J., Kim, I., Wu, G., Toyoda, M., Shin, B., & Vo, A. (2017) · Transplantation · doi:10.1097/tp.0000000000001452 · Cited by 260
Innate Immune Cells in Liver Inflammation
Liaskou, E., Wilson, D. V., & Oo, Y. H. (2012) · Mediators of Inflammation · doi:10.1155/2012/949157 · Cited by 255
IL-6 Improves Energy and Glucose Homeostasis in Obesity via Enhanced Central IL-6 trans-Signaling
Timper, K., Denson, J. L., Steculorum, S. M., Heilinger, C., Engström-Ruud, L., Wunderlich, C. M., Rose-John, S., Wunderlich, F. T., & Brüning, J. C. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.03.043 · Cited by 233
Self-citationAffibody molecules as engineered protein drugs
Frejd, F. Y., & Kim, K.-T. (2017) · Experimental & Molecular Medicine · doi:10.1038/emm.2017.35 · Cited by 225
The soluble interleukin 6 receptor: advanced therapeutic options in inflammation
Rose‐John, S. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.782 · Cited by 169
Self-citationGarbers, C., Monhasery, N., Aparicio-Siegmund, S., Lokau, J., Baran, P., Nowell, M. A., Jones, S. A., Rose-John, S., & Scheller, J. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.05.018 · Cited by 155
Self-citationPeriodontal therapy and cardiovascular risk
Orlandi, M., Graziani, F., & D'Aiuto, F. (2020) · Periodontology 2000 · doi:10.1111/prd.12299 · Cited by 155
Gupta, S., Hirota, M., Waugh, S. M., Murakami, I., Suzuki, T., Muraguchi, M., Shibamori, M., Ishikawa, Y., Jarvis, T. C., Carter, J. D., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.532580 · Cited by 151
“The humanized anti-IL-6 receptor antibody tocilizumab has afforded some benefit to patients with rheumatoid arthritis, Castleman disease, and juvenile idiopathic arthritis (45).”
BackgroundNovel antiatherosclerotic therapies
Libby, P., & Everett, B. M. (2019) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.118.310958 · Cited by 145
The problem of choice: current biologic agents and future prospects in RA
Choy, E. H., Kavanaugh, A. F., & Jones, S. A. (2013) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2013.8 · Cited by 141
Self-citationTargeting classical IL-6 signalling or IL-6 trans-signalling in depression?
Maes, M., Anderson, G., Kubera, M., & Berk, M. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.888417 · Cited by 140
Kothari, P., Pestana, R., Mesraoua, R., Elchaki, R., Khan, K. M. F., Dannenberg, A. J., & Falcone, D. J. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1301906 · Cited by 137
Proteolytic Origin of the Soluble Human IL-6R In Vivo and a Decisive Role of N-Glycosylation
Riethmueller, S., Somasundaram, P., Ehlers, J. C., Hung, C.-W., Flynn, C. M., Lokau, J., Agthe, M., Düsterhöft, S., Zhu, Y., Grötzinger, J., et al. (2017) · PLOS Biology · doi:10.1371/journal.pbio.2000080 · Cited by 135
Self-citationGarcia-Oscos, F., Salgado, H., Hall, S., Thomas, F., Farmer, G. E., Bermeo, J., Galindo, L. C., Ramirez, R. D., D'Mello, S., Rose-John, S., et al. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.11.018 · Cited by 105
Self-citationCellular Senescence as a Therapeutic Target for Age-Related Diseases: A Review
Amaya-Montoya, M., Pérez-Londoño, A., Guatibonza-García, V., Vargas-Villanueva, A., & Mendivil, C. O. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01287-0 · Cited by 82
Molecular insights into the multilayered regulation of ADAM17: The role of the extracellular region
Grötzinger, J., Lorenzen, I., & Düsterhöft, S. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2017.05.024 · Cited by 76
Lamertz, L., Rummel, F., Polz, R., Baran, P., Hansen, S., Waetzig, G. H., Moll, J. M., Floss, D. M., & Scheller, J. (2018) · Science Signaling · doi:10.1126/scisignal.aar7388 · Cited by 70
Self-citationThe interleukin 6 pathway and atherosclerosis
Scheller, J., & Rose-John, S. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61246-x · Cited by 56
Self-citationLin, W. W., Yi, Z., Stunz, L. L., Maine, C. J., Sherman, L. A., & Bishop, G. A. (2015) · Science Signaling · doi:10.1126/scisignal.aaa5157 · Cited by 50
The Hierarchy of Proinflammatory Cytokines in Ocular Inflammation
Da Cunha, A. P., Zhang, Q., Prentiss, M., Wu, X. Q., Kainz, V., Xu, Y. Y., Vrouvlianis, J., Li, H., Rangaswamy, N., Leehy, B., et al. (2018) · Current Eye Research · doi:10.1080/02713683.2017.1410180 · Cited by 40
Wang, P., Feng, Y.-B., Wang, L., Li, Y., Fan, C., Song, Q., & Yu, S. Y. (2019) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2019.08.002 · Cited by 38
The Regenerative Activity of Interleukin-6
Galun, E., & Rose-John, S. (2013) · Methods in Molecular Biology · doi:10.1007/978-1-62703-308-4_4 · Cited by 34
Self-citationYavropoulou, M. P., Filippa, M. G., Mantzou, A., Ntziora, F., Mylona, M., Tektonidou, M. G., Vlachogiannis, N. I., Paraskevis, D., Kaltsas, G. A., Chrousos, G. P., et al. (2022) · Endocrine · doi:10.1007/s12020-021-02968-8 · Cited by 33
Lack of gp130 expression in hepatocytes attenuates tumor progression in the DEN model
Hatting, M., Spannbauer, M., Peng, J., Al Masaoudi, M., Sellge, G., Nevzorova, Y. A., Gassler, N., Liedtke, C., Cubero, F. J., & Trautwein, C. (2015) · Cell Death & Disease · doi:10.1038/cddis.2014.590 · Cited by 30
“poor prognosis in humans, processes which are linked to the gp130-signaling pathway.(3) Moreover, somatic mutations cod-”
BackgroundTaylor, P. C., Schiff, M. H., Wang, Q., Jiang, Y., Zhuang, Y., Kurrasch, R., Daga, S., Rao, R., Tak, P. P., & Hsu, B. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-212496 · Cited by 28
Ferreira, R. C., Rainbow, D. B., Rubio García, A., Pekalski, M. L., Porter, L., Oliveira, J. J., Waldron-Lynch, F., Wicker, L. S., & Todd, J. A. (2017) · Clinical Immunology · doi:10.1016/j.clim.2017.03.002 · Cited by 19
“These results indicate that inhibition of IL-6 signalling could be a therapeutic approach in T1D, as it is in other human inflammatory diseases [42,43].”
Result
Metadata
- Authors
- Jones, S. A., Scheller, J., & Rose-John, S.
- Venue
- Journal of Clinical Investigation
- Published
- 2011-09-01
- Volume
- 121
- Issue
- 9
- Pages
- 3375-3383
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W1971308765
- Cited by
- 683
- References
- 125
- FWCI
- 25.37
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.